CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Abstract

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-label trial, insulin-naive adults (≥18 years of age) with type 2 diabetes (T2D) uncontrolled on metformin (with or without a sulphonylurea) were randomized 1:1:1:1 to weekly tirzepatide 5 mg, 10 mg or 15 mg or daily insulin glargine at 66 hospitals in China, South Korea, Australia and India. The primary endpoint was non-inferiority of mean change in hemoglobin A1c (HbA1c) from baseline to week 40 after treatment with 10 mg and 15 mg of tirzepatide. Key secondary endpoints included non-inferiority and superiority of all tirzepatide doses in HbA1c reduction, proportions of patients achieving HbA1c < 7.0% and weight loss at week 40. A total of 917 patients (763 (83.2%) in China) were randomized to tirzepatide 5 mg (n = 230), 10 mg (n = 228) or 15 mg (n = 229) or insulin glargine (n = 230). All doses of tirzepatide were non-inferior and superior to insulin glargine for least squares mean (s.e.) reduction in HbA1c from baseline to week 40: tirzepatide 5 mg, 10 mg and 15 mg, -2.24% (0.07), -2.44% (0.07) and -2.49% (0.07), respectively, and insulin glargine, -0.95% (0.07), with a treatment difference ranging from -1.29% to -1.54% (all P < 0.001). Proportions of patients achieving HbA1c < 7.0% at week 40 were greater in tirzepatide 5-mg (75.4%), 10-mg (86.0%) and 15-mg (84.4%) groups compared to insulin glargine (23.7%) (all P < 0.001). All tirzepatide doses led to superior body weight reductio…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02344-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 3

  1. IDF Diabetes Atlas, 10th edition. International Diabetes Federation https://www.diabetesatlas.org (2021).
  2. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin. J. Diabetes Mellit. 13, 315–409 (2021).
  3. Ji, L. N. & Zou, D. J. Consensus of chinese experts on the remission of type 2 diabetes mellitus. Chin. Gen. Pract. 24, 11 (2021).

Cited by

See all 104

Metadata

Authors
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L.
Affiliations
  • Peking University People's Hospital (CN)
  • Severance Hospital (KR)
  • Lilly (China) (CN)
Corresponding author
Ji, Linong
Venue
Nature Medicine
Published
2023-05-25
Volume
29
Issue
6
Pages
1500-1510
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4378212143
Cited by
104
References
33
Citations by year
2026: 24 · 2025: 36 · 2024: 38 · 2023: 6
FWCI
21.15
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company (NA)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, insulin glargine, type 2 diabetes, GIP/GLP-1 receptor agonist, second-line therapy, third-line therapy, insulin-naive patients, metformin, sulfonylureas, HbA1c, weight loss, non-inferiority, Asia-Pacific region, China, South Korea
MeSH terms
Insulin Glargine, Tirzepatide, Adult, Asia, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Infant, Newborn

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. https://app.cochat.ai/papers/10.1038/s41591-023-02344-1
The paper
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023). Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02344-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.